1. Israel Stocks

  2. •

    Financial Services

  3. •

    Asset Management
The Trendlines Group Ltd.

The Trendlines Group Ltd.

42T.SI
The Trendlines Group Ltd.SG flagStock Exchange of Singapore
0.06
SGD
- -
- -
82.96MMarket Cap
The Trendlines Group Ltd.
42T.SI
(Stock Exchange of Singapore)

Recent

price

0.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.02
0.01
0.01
0.01
0.01
0.01
- -
- -
- -
- -
- -
- -
0.01
Revenue per Share
-0.01
-0.01
-0.01
0.01
-0.01
- -
- -
0.01
-0.02
-0.03
-0.01
- -
- -
Basic EPS, GAAP
-0.02
-0.02
-0.02
-0.01
-0.01
-0.01
- -
- -
-0.02
-0.01
-0.01
-0.01
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.08
0.07
0.04
0.04
0.03
0.02
0.02
0.02
0.01
-0.03
-0.04
-0.03
0.02
Book Value per Share
0.16
0.22
0.15
0.17
0.14
0.15
0.12
0.13
0.11
0.07
0.07
0.07
0.13
Tangible Book Value per Share
347
375
521
538
624
671
811
811
861
984
1,026
1,168
753
Basic Weighted Avg Shares
6
5
7
6
7
6
4
2
4
4
2
- -
7
Sales/Revenue/Turnover
-44.34
42.44
-149.24
89.02
-85.76
14.69
-426.38
-65.67
-346.2
-762.66
-622.69
22.29
-7.11
Operating Margin (%)
- -
- -
- -
- -
- -
1
1
1
1
1
1
1
1
Depreciation Expense
-3
-3
-7
4
-6
- -
-4
7
-14
-34
-9
2
-3
Net Income, GAAP
- -
- -
- -
29.47
- -
607.3
- -
- -
- -
- -
- -
- -
27.68
Effective Tax Rate (%)
-47.28
-72.31
-91.23
65.75
-81.79
-8.62
-97.14
285.22
-404.7
-756.12
-548.28
548
-40
Profit Margin (%)
- -
20
12
14
6
15
11
12
6
4
3
3
13
Working Capital
6
4
4
4
3
6
5
5
4
4
3
4
6
LT Debt
56
84
78
93
86
100
96
103
96
69
68
77
96
Total Equity
- -
- -
- -
4.11
- -
-4.2
- -
- -
- -
- -
- -
0.1
- -
Return on Invested Capital (%)
- -
- -
- -
15.19
- -
-5.49
- -
- -
- -
- -
- -
-7.54
5.61
Return on Capital (%)
- -
-12.63
-30.2
18.78
-31.26
-2.87
-25.4
40.73
-117.91
- -
- -
- -
-19.38
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'19
Mar'20
Jun'20
ST Debt
- -
- -
1
LT Borrowings
4
- -
3
LT Finance Leases
2
- -
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
811
- -
811
Market Capitalization
46
38
58

Working Capital

FRC

•

in mil. unless spec.
Dec'19
Mar'20
Jun'20
Total Current Assets
20
- -
17
Cash, Cash Equivalents & STI
19
- -
8
Accounts Receivable, Net
- -
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
5
- -
3
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
0.09%
-3.16%
13.7%
Free Cash Flow
-2,003.64%
-4,001.29%
1.87%
Net Income, GAAP
-37.65%
-130.85%
-120.35%
Sales/Revenue/Turnover
-9.01%
-20.08%
-79.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
4
2024
- -
- -
- -
- -
2
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.03
2024
- -
- -
- -
- -
-0.01
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
John Hancock Investments - Multifactor Small Cap ETF (JHSC)
Leverage Shares 3x Royal Dutch Shell ETP (3RDS.L)
Marsico Focus Fund (MFOCX)
iShares Edge MSCI World Minimum Volatility UCITS ETF EUR Hedged Accum (SXR0.DE)
Emerge EMPWR Sustainable Global Core Equity ETF (EMZA)
TD One-Click Conservative ETF Portfolio (TOCC.TO)
Business
The Trendlines Group Ltd. The Trendlines Group Ltd. is an Israel-based life sciences innovation commercialization company that invents, discovers, invests in, partners with, and incubates early-stage medical technologies (medtech) and agrifood technologies; it operates principally through four business units including Israeli government-franchised incubators Trendlines Medical and Trendlines Agtech, a Singapore incubator Trendlines Medical Singapore, and an in-house innovation center Trendlines Labs. The company maintains a portfolio of more than 50 companies focused on medtech areas such as cardiology, neurology and anesthesia, esthetics, gastroenterology, home healthcare, spine and orthopedics, surgery, urology and women's health; and agrifood areas including aquaculture and animal health, crop protection, digitization and robotics, future food and ingredients, and net-zero technologies, with representative portfolio companies encompassing AgroScout (AI-driven crop disease detection), Phytolon (natural food colors from yeast fermentation), Escala Medical (non-surgical pelvic organ prolapse repair), Vensica Medical (overactive bladder treatment), and EcoPhage (phage-based crop protection). Founded in 1993 and headquartered at 17 T’chelet Street in M.P. Misgav, Israel, with additional offices in Tel Aviv, Israel; Singapore; and formerly Beijing, China, the group provides comprehensive support to its portfolio companies encompassing technology development, business building, funding strategies, market commercialization, and administrative services while targeting entrepreneurs, inventors, investors, strategic partners, and governments primarily in Israel and Singapore. Recent developments include portfolio company Escala Medical securing $4.5 million in funding co-financed by the EIC Fund in June 2025 to expand its FDA-approved Mendit device for women's health; IBI Ag raising $6.1 million in initial Series A funding led by Corteva in 2025; Arcuro Medical closing an initial Series A round led by Varana Capital with Trendlines participation; ElastiMed appointing medical device veteran Dr. Amir Belson to its board amid commercialization preparations; and Vensica Medical raising $11 million led by Israel Biotech Fund to advance Phase 2 trials for overactive bladder therapy, alongside ongoing exits such as the prior acquisitions of OrthoSpin by DePuy Synthes (Johnson & Johnson) in November 2021 and ApiFix by OrthoPediatrics Corp. in 2020.